What Makes Life Sciences Tools a Distinctive Healthcare Subsector?

Life sciences tools companies — instrument manufacturers, reagent suppliers, contract research organizations, and laboratory services providers — occupy an unusual position in Healthcare: they serve as picks-and-shovels infrastructure for pharmaceutical and biotech drug development rather than making drugs themselves. This positioning means life sciences tools companies benefit from pharmaceutical industry growth without the binary clinical risk of drug development. However, it also means they face exposure to biotech funding cycles — when biotech capital dries up, laboratory equipment purchases and reagent orders slow, creating cyclical headwinds that are less relevant for large pharmaceutical companies with stable R&D budgets.

Quick definition: Life sciences tools companies provide the instruments (mass spectrometers, flow cytometers, sequencers, bioreactors), reagents (antibodies, cell culture media, assay kits), and services (contract manufacturing, clinical research) that enable pharmaceutical and biotech drug development. Their revenue grows with overall R&D spending — providing exposure to pharmaceutical industry expansion without drug approval binary risk.

Key takeaways

• Thermo Fisher Scientific is the world's largest life sciences tools company — approximately $44+ billion in revenue — providing end-to-end laboratory solutions from basic research supplies to contract pharmaceutical manufacturing
• Danaher's diversified diagnostics and life sciences platform, operated through the Danaher Business System (DBS) operational excellence framework, has compounded earnings at approximately 15%+ annually over multiple decades through acquisitions and organic improvement
• Life sciences tools companies face biotech customer cycle exposure — when VC funding and public biotech capital declines (as in 2022–2023), biotech companies reduce laboratory purchases, creating revenue headwinds
• Contract Research Organizations (CROs — IQVIA, Charles River Laboratories, Icon) manage pharmaceutical clinical trials for a fee — growing as pharmaceutical companies outsource clinical development rather than maintaining in-house capacity
• Life sciences tools valuation premiums (typically 25–40x EV/EBITDA historically) reflect the sector's stable growth, high recurring revenue from consumables, and low customer concentration

Thermo Fisher Scientific's business model

Four-segment structure: Thermo Fisher operates four segments: Life Sciences Solutions (biosciences reagents, cell culture, genetic analysis tools); Analytical Instruments (mass spectrometers, electron microscopes, chromatography); Laboratory Products and Biopharma Services (laboratory supplies distribution, contract pharmaceutical manufacturing — Patheon); and Specialty Diagnostics (clinical diagnostics, transplant diagnostics). This diversification across research tools, analytical instruments, distribution, and manufacturing services creates revenue stability through the pharmaceutical R&D cycle.

Reagent and consumable recurring revenue: Approximately 60–70% of Thermo Fisher revenue is from consumables, services, and reagents — recurring revenue that renews automatically as customers run experiments and deplete supplies. This recurring revenue base provides stability relative to pure instrument businesses where new system sales can be deferred during capital constraints.

PPD and contract research: Thermo Fisher acquired PPD (Pharmaceutical Product Development) in 2021 for approximately $21 billion — expanding into clinical research organization (CRO) services. This acquisition positioned Thermo Fisher as a full-service partner for pharmaceutical companies from early-stage research through clinical development and manufacturing, deepening relationships and expanding addressable market.

COVID-19 revenue and normalization: Thermo Fisher generated approximately $9+ billion in COVID-related revenue (PCR testing supplies, vaccine manufacturing services) during 2020–2022 — elevated earnings that subsequently normalized as COVID demand declined in 2023–2024. Investors in Thermo Fisher must separate COVID-driven revenue from core business performance when evaluating the company's organic growth trajectory.

Acquisitions as growth engine: Thermo Fisher has grown substantially through acquisitions — Fisher Scientific (2006, laboratory supplies), Life Technologies (2014, genomics reagents), FEI Company (2016, electron microscopes), Patheon (2017, contract manufacturing), PPD (2021, CRO). Each acquisition expanded the workflow platform and cross-selling opportunities. Thermo Fisher's acquisition track record demonstrates consistent value creation from integrating complementary businesses into the workflow ecosystem.

Danaher's operating system model

Danaher Business System (DBS): Danaher's competitive differentiation lies in its operating system — a lean manufacturing and continuous improvement methodology adapted from Toyota Production System principles. DBS provides a systematic framework for quality improvement, cost reduction, and productivity enhancement that Danaher applies to every acquired business. The operating system creates a platform for sustained margin improvement that generates ROIC well above cost of capital.

Portfolio evolution: Danaher has transformed its portfolio substantially — divesting diversified industrial businesses and concentrating in life sciences, diagnostics, and environmental analytics. The 2019 acquisition of GE BioPharma (bioprocessing equipment and consumables) for approximately $21.4 billion was a transformative addition to Danaher's life sciences platform. Danaher subsequently spun off its dental and diversified industrial businesses (Fortive, Envista) to sharpen the life sciences focus.

Bioprocessing exposure: Through its Cytiva division (formed from GE BioPharma), Danaher is the leading supplier of bioprocessing equipment and consumables — the instruments and single-use materials used to manufacture biological drugs. As biologic drug production grows (more biologics approvals, GLP-1 manufacturing expansion), bioprocessing demand grows proportionally. Cytiva's market position is dominant — single-use bioreactors, filtration equipment, and process analytical tools are Cytiva products.

Beckman Coulter and diagnostics: Danaher's Beckman Coulter division provides clinical chemistry and immunoassay analyzers for hospital laboratories. This diagnostics business generates high recurring revenue from reagent kits required for analyzer operation — the classic razor-and-blade consumables model where analyzer placements drive long-term reagent revenue.

How it flows

Contract Research Organizations

CRO business model: Contract Research Organizations manage pharmaceutical clinical trials — Phase 1 through Phase 3 — for pharmaceutical and biotech clients who outsource clinical development to reduce internal headcount and access specialized expertise. CROs employ physicians, statisticians, data managers, and regulatory writers who run clinical programs under contract. Major CROs include IQVIA, Charles River Laboratories (preclinical focus), Icon, Syneos Health, and PRA Health Sciences (now part of ICON).

Outsourcing growth trend: Pharmaceutical industry outsourcing of R&D activities has grown from approximately 30% outsourced in 2000 to approximately 50–65% outsourced by the 2020s — a structural shift driven by cost efficiency (CRO employees are more cost-effective than in-house staff at fixed overhead cost), flexibility (outsourcing scales with the number of active trials), and specialized expertise access.

Biotech customer concentration risk: Small to mid-size biotech companies represent a substantial and growing share of CRO revenue — these clients may represent 30–50% of total CRO backlogs. When biotech funding declines (as in 2022–2023), biotech clients cancel or slow trials, reducing CRO revenue. This biotech funding cycle exposure creates CRO revenue volatility that is correlated with biotech equity market conditions.

IQVIA's data business: IQVIA differentiates from other CROs through its Real World Evidence and data analytics business — aggregating prescription data, electronic health records, and claims data to provide pharmaceutical companies with insights about drug utilization, patient outcomes, and market dynamics. This data business generates recurring subscription revenue with different characteristics than project-based CRO services.

Biotech customer cycle exposure

2022–2023 biotech funding contraction: The 2022 rate-driven biotech market decline reduced small biotech company capital availability — companies that had been burning cash from equity raises found new financings more difficult and dilutive. In response, biotech companies reduced laboratory expenses: deferred equipment purchases, reduced reagent orders, and slowed clinical program timelines. Thermo Fisher, Danaher, Agilent Technologies, and Waters Corporation all reported biotech customer ordering slowdowns in their 2023 earnings — contributing to earnings guidance cuts.

Large pharma insulation: While biotech customers slowed orders, large pharmaceutical company R&D budgets were more stable — companies like Pfizer, Merck, and AbbVie had multi-year R&D investment plans that were less sensitive to near-term capital market conditions. Life sciences tools companies with higher large pharmaceutical customer concentration were more insulated from the 2022–2023 biotech funding cycle headwind.

Recovery indicators: Recovery in biotech funding (public biotech IPO activity, biotech stock price recovery, VC fund deployment acceleration) leads recovery in laboratory equipment and reagent orders. Monitoring biotech funding conditions provides a leading indicator for life sciences tools company revenue recovery — typically 6–12 months after funding environment improves, laboratory spending normalizes.

Valuation characteristics

Historical premium multiples: Life sciences tools companies have historically commanded significant valuation premiums relative to the broader market — EV/EBITDA multiples of 25–40x for high-quality companies like Thermo Fisher and Danaher. These premiums reflect: (1) high recurring consumable revenue providing earnings visibility; (2) competitive moats from workflow integration; (3) structural pharmaceutical R&D spending growth as a secular tailwind; and (4) acquisition-driven growth with demonstrated value creation.

Multiple compression in 2022–2023: Life sciences tools multiples compressed significantly in 2022–2023 as COVID revenue normalized, biotech customer cycle headwinds appeared, and rate increases reduced premium growth stock valuations broadly. Thermo Fisher and Danaher saw EV/EBITDA multiples compress from peak levels of approximately 30–35x to approximately 20–25x — creating potential valuation re-entry opportunities for long-term investors.

Organic growth rate assessment: For life sciences tools companies, separating organic growth (excluding acquisitions and COVID revenue) from total reported growth is critical for valuation analysis. Companies that grew 15–20% during COVID through testing supplies and vaccine manufacturing may show 0–5% "organic" growth in normalization years — making the underlying business growth rate appear weaker than the structural R&D spending tailwind warrants.

Common mistakes

Conflating life sciences tools cyclicality with pharmaceutical defensiveness. Life sciences tools companies are more cyclical than large pharmaceutical companies — biotech customer funding cycles, academic research budget constraints (government funding sequestration), and instrument purchase deferrals during capital stress create meaningful revenue cyclicality. Investors expecting pharmaceutical-equivalent defensiveness from tools companies will be surprised by the greater earnings volatility.

Using COVID-era revenue as the normalization base. Thermo Fisher, Danaher, and other life sciences tools companies with significant COVID testing or vaccine manufacturing revenue generated dramatically elevated 2020–2022 earnings. Using these years as the base for growth rate calculations or as the earnings denominator in valuation multiples overstates the sustainable earnings power of the underlying business.

FAQ

What is the distinction between life sciences tools and medical diagnostics?

Life sciences tools serve research and development customers (pharmaceutical companies, academic research institutions, government laboratories) — their products are used to discover and develop drugs rather than to diagnose patients. Clinical diagnostics companies serve hospital laboratories and physician offices — their products are used in patient care decisions. There is overlap at large companies (Thermo Fisher, Danaher, Abbott serve both markets), but the customer base, reimbursement dynamics, and regulatory requirements differ substantially. FDA device approvals and clinical validation requirements apply to diagnostic products; research tools face less stringent regulatory requirements. FDA device classification guidance at fda.gov explains the regulatory distinction.

Related concepts

• Healthcare Overview
• Pharmaceutical and Biotech Analysis
• Healthcare Interest Rates
• Healthcare ETFs
• Healthcare Innovation Cycles

Summary

Life sciences tools companies (Thermo Fisher, Danaher, IQVIA, Agilent) serve as research infrastructure for pharmaceutical and biotech drug development — providing instruments, reagents, and services that grow with overall R&D spending. Thermo Fisher's end-to-end workflow platform (approximately 60–70% recurring consumable revenue) and Danaher's Business System-driven operational excellence have produced decades of compounding earnings growth. The sector faces biotech customer cycle exposure — when biotech funding declines (2022–2023), laboratory purchases slow and create earnings headwinds that are distinct from large pharmaceutical company budget stability. CROs (IQVIA, ICON, Charles River) represent a related picks-and-shovels segment managing outsourced clinical development. Life sciences tools premium valuations (historically 25–40x EV/EBITDA) reflect recurring revenue visibility and structural pharmaceutical R&D growth tailwinds — though COVID revenue normalization and biotech customer cycles create meaningful earnings volatility that investors must account for.

Next

→ Healthcare Innovation Cycles: From HIV to GLP-1 and Beyond